Stage IV ALK Non-Small Cell Lung Cancer: Alisa's Patient Story

Patient Info: Alisa Secaida, Female, Under 40 | Stage IV

Biomarkers: ALK-positive / ALK-rearranged

Metastatic Site: Brain; lymph nodes

As of May 2025, after alectinib and lung surgery, pathology still showed active tumor and lymph-node cancer cells, and Alisa was receiving IMRT for remaining disease.

City of HopeRead more →

Metastatic ER-positive pleomorphic lobular breast cancer: psoas metastasis and stable disease on eribulin

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary and chest-wall recurrence were ER/PR positive, HER2 negative. Later psoas metastasis was ER positive, PR/HER2 negative.

Metastatic Site: skin of left chest wall; bone; left psoas muscle;…

As of May 2025, one year after diagnosis of malignant psoas syndrome from breast cancer metastasis, she remained on outpatient treatment with eribulin and had stable disease.

PubMed CentralRead more →

Stage II BRCA2 Invasive Ductal Carcinoma: Onjalai's Survivor Story

Patient Info: Onjalai Brown, Female, Under 40 | Stage II

Biomarkers: Patient-specific biomarker/genetic result not reported; family history suggests BRCA2 mutation

After lumpectomy, 20 rounds of chemotherapy and 36 rounds of radiation for Stage II invasive ductal carcinoma with lymph-node involvement, Onjalai had been cancer-free for 3 years as of May 2025.

City of HopeRead more →

Ductal Carcinoma In Situ Treated With Mastectomy Using Vein-Mapping Guidance

Patient Info: Anonymized, Female, 60s

A 68-year-old woman with extensive ductal carcinoma in situ underwent mastectomy using a vein-visualization technique intended to reduce vascular injury during surgery.

PubMed CentralRead more →

Extensive Ductal Carcinoma In Situ Removed With Vein-Based Surgical Mapping

Patient Info: Anonymized, Female, 40s

A 41-year-old woman with extensive ductal carcinoma in situ had the lesion mapped against superficial breast veins to guide surgical removal.

PubMed CentralRead more →

Luminal A Breast Cancer Treated With Endocrine Therapy Before Partial Mastectomy

Patient Info: Anonymized, Female, 50s

Biomarkers: luminal A

A 56-year-old woman with luminal A invasive ductal breast cancer had marked tumor shrinkage after 3 months of endocrine therapy before partial mastectomy.

PubMed CentralRead more →

Stage IA invasive lobular breast cancer with ipsilateral marginal zone lymphoma: no recurrence after surgery and radiation

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: Breast cancer was ER-positive, PR-negative, HER2-negative. Separate marginal zone lymphoma showed CD20/Bcl-2 markers

As of May 2025, five-month follow-up imaging showed no recurrence of the right breast invasive lobular carcinoma and no clinical recurrence of the ipsilateral marginal zone lymphoma.

PubMed CentralRead more →

Poorly Differentiated Lung Adenocarcinoma Recurring After Surgery and Chemotherapy

Patient Info: Anonymized, male, 60s

Biomarkers: No driver mutation identified initially; recurrent tumor PD-L1 >50%

The cancer recurred in June 2024 with a para-aortic mass and enlarged mediastinal and supraclavicular lymph nodes. Camrelizumab was started, but he could not tolerate it and declined further treatment.

PubMed CentralRead more →

Poorly Differentiated Lung Adenocarcinoma Without Recurrence After Surgery and Chemotherapy

Patient Info: Anonymized, male, 60s

Biomarkers: No driver mutation identified; PD-L1 at least 1%

No signs of recurrence were observed through April 2025 after surgery and 4 cycles of adjuvant chemotherapy.

PubMed CentralRead more →

Triple-negative sebaceous carcinoma of the breast: no recurrence after multimodality treatment

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative sebaceous breast carcinoma; EMA-positive; Ki-67 50-60%; inherited breast/ovarian cancer testing negative for pathogenic variants.

As of May 2025, after surgery, adjuvant chemotherapy, and radiation, she had 5 years of follow-up with no evidence of neoplastic recurrence.

PubMed CentralRead more →

Triple-Negative Breast Cancer: Lauren's Survivor Story

Patient Info: Lauren Yerkes, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative

As of May 2025, Lauren Yerkes was a triple-negative breast cancer survivor and founder of POST SWIM, a swimwear brand created from her post-mastectomy experience.

Breast Cancer: Honey's Survivor Story

Patient Info: Honey, Female

Honey completed surgical treatment for breast cancer with clear lymph nodes and margins. She declined radiation and chemotherapy, later stopped tamoxifen, and focused on recovery from surgical menopause symptoms and returning to art. No recurrence or metastatic disease was described.

The Patient StoryRead more →

Metastatic rectal cancer responding well after intensive treatment despite severe chemotherapy complications

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: KRAS exon 4 mutation, BRAF wild-type, PD-L1 CPS 2

Metastatic Site: liver, lung

After more than 14 months of treatment, the primary rectal tumor and most lung metastases had been resected, liver lesions had largely regressed, and he was described as near NED while continuing maintenance capecitabine plus bevacizumab.

PubMed CentralRead more →

Stage IIIB ER/PR-positive breast cancer: emergency mastectomy for infected fungating tumor

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: ER >75%; PR >75%; HER2 0 / HER2-negative; grade 3 invasive ductal carcinoma

As of May 2025, management centered on anastrozole after emergency mastectomy, repeated debridements, wound care, and major postoperative complications; oncology follow-up had become inconsistent because of ongoing medical setbacks.

PubMed CentralRead more →

Localized sarcomatoid lung carcinoma: no recurrence 14 months after lobectomy

Patient Info: Anonymized, Male, 50s

Biomarkers: No molecular biomarkers reported; histopathology confirmed sarcomatoid carcinoma

As of May 2025, the patient remained in good health with no evidence of recurrence 14 months after video-assisted thoracoscopic left lower lobectomy.

PubMed CentralRead more →

Stage I Breast Cancer: Krista's Patient Story

Patient Info: Krista, Female | Stage I

Biomarkers: ATM mutation; hormone receptor-positive; HER2-negative; Oncotype DX score 1

As of May 2025, Krista had undergone double mastectomy with flap reconstruction for Stage IA hormone receptor-positive, HER2-negative breast cancer and was taking tamoxifen with minimal early side effects.

The Patient StoryRead more →

Recurrent breast cancer with pleural disease: capecitabine stopped after cardiac complications

Patient Info: Anonymized, Female, 50s | Stage IV

Metastatic Site: pleura

As of May 2025, she was living with recurrent breast cancer involving the pleura after stopping capecitabine because of major cardiac complications; cardiac symptoms were medically managed with stable NYHA class II dyspnea at 3-month follow-up.

PubMed CentralRead more →

Stage II HR-Positive Breast Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of May 2025, Kelsey had completed chemotherapy, double mastectomy with reconstruction, and 16 radiation sessions, and was continuing tamoxifen with Verzenio planned for 2 years plus Lupron ovarian-suppression shots.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: LaShae's Patient Story

Patient Info: LaShae, Female, Under 40 | Stage II

Biomarkers: ER-positive; comprehensive genetic panel negative

As of May 2025, LaShae had completed mastectomy for Stage IIB ER-positive breast cancer with 2 positive lymph nodes and was undergoing chemotherapy, with radiation and 5-10 years of hormone therapy planned.

The Patient StoryRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Samantha's Patient Story

Patient Info: Samantha, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Rib; spine; pelvis

After a mixed response on the radium trial, Samantha changed to anastrozole and abemaciclib. She described the newer hormone-targeted combination as easier to tolerate and working better while remaining in ongoing treatment.

The Patient StoryRead more →

Stage III HR-Positive Breast Cancer: Christine's Survivor Story

Patient Info: Christine, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-positive

Three years after diagnosis, Christine described herself in the survivorship stage and focused on the physical and emotional effects that continued after active treatment.

The Patient StoryRead more →

Colorectal Cancer: Crystal's Survivor Story

Patient Info: Crystal, Female

Crystal completed limited chemotherapy and multiple major surgeries for colon cancer complicated by bladder involvement and infection risk. She lost her bladder and adapted to ostomy changes. No explicit NED, recurrence, or active-disease status was given.

The Patient StoryRead more →

Stage II Colorectal Cancer: Marc's Survivor Story

Patient Info: Marc Anthony, Male, Under 40 | Stage II

Biomarkers: Lynch syndrome

Marc Anthony had Stage IIA colon cancer treated with surgery alone. He did not need chemotherapy or radiation, later learned he had Lynch syndrome, and continued awareness/surveillance because of hereditary risk.

The Patient StoryRead more →

Stage IV Colorectal Cancer: Esteban's Survivor Story

Patient Info: Esteban Moreno | Stage IV

Biomarkers: Lynch syndrome

After immunotherapy and surgery for Stage IV colorectal cancer, Esteban reported recent scans showing no signs of cancer and described himself as NED.

Fight Colorectal CancerRead more →